stockrowBio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.
- Revenue
- +1.33%
- EPS
- +418.2%
- Free cash flow
- −6.83%
- Total debt
- −42.2%
Quarter to June 2026, against a year earlier
Follow TECH
Alert me
Bio-Techne Corp (TECH) Return on equity
Bio-Techne Corp's return on equity over the twelve months to 30 June 2026 was 9.03%. Over the past ten years it has ranged from 3.68% (fiscal 2025) to 18.0% (fiscal 2020); the current reading is higher than 42% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | 9.03% | 5.35 |
| FY2025 | 3.68% | (4.65) |
| FY2024 | 8.33% | (7.23) |
| FY2023 | 15.6% | (1.07) |
| FY2022 | 16.6% | 7.12 |
| FY2021 | 9.51% | (8.50) |
| FY2020 | 18.0% | 9.45 |
| FY2019 | 8.56% | (3.88) |
| FY2018 | 12.4% | 4.12 |
| FY2017 | 8.32% | (3.78) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| IBRX ImmunityBio, Inc. compare | 122.9% |
| TGTX TG Therapeutics, Inc. compare | 100.3% |
| TECH Bio-Techne Corp | 9.03% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.31% |
| KYMR Kymera Therapeutics, Inc. compare | −27.3% |
| TWST Twist Bioscience Corporation compare | −29.6% |
| PCVX Vaxcyte, Inc. compare | −36.5% |
| SMMT Summit Therapeutics PLC compare | −192.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement